Starling Oncology (STLNW) Receivables (2020 - 2026)

Starling Oncology (STLNW) has reported Receivables for 7 consecutive years, with $66.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 19.26% year-over-year to $66.7 million; the trailing twelve-month figure through Jun 2026 stood at $66.7 million (up 19.26% YoY), and the FY2025 full-year result was $59.3 million, up 21.85% from the prior year.
• Receivables climbed to $66.7 million in Q2 2026 per STLNW's latest filing, from $59.4 million in the prior quarter.
• Across five years, Receivables topped out at $66.7 million in Q2 2026 and bottomed at $25.8 million in Q1 2022.
• Historically, Receivables has averaged $49.0 million across 5 years, with a median of $49.3 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Receivables soared 94.7% in 2022, then decreased 16.0% in 2025.
• Over 5 years, Receivables stood at $39.9 million in 2022, then increased by 6.45% to $42.4 million in 2023, then increased by 13.84% to $48.3 million in 2024, then advanced by 22.06% to $59.0 million in 2025, then increased by 13.1% to $66.7 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $66.7 million, $59.4 million, and $59.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.